# US 2017/0281601 A1 · Novel compounds and compositions and methods of use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2017/0281601 A1
- Document ID: US20170281601A1
- Status: Published application
- Kind: A1
- Application number: 15/358,586
- Filed: 2016-11-22
- Published: 2017-10-05
- Earliest claimed: 2007-11-27
- Assignees: Ardea Biosciences, Inc.
- Applicants: Ardea Biosciences, Inc.
- Inventors: Barry D. QUART; Jean-Luc GIRARDET; Esmir GUNIC; Li-Tain YEH
- Web page: https://patentgrep.com/patent/US20170281601A1

## CPC

- A61K 31/4196: 1,2,4-Triazoles
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/7068: having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K 31/7072: having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
- A61K 31/7076: containing purines, e.g. adenosine, adenylic acid
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/20: for decreasing, blocking or antagonising the activity of PTH
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 9/12: Antihypertensives
- A61P 13/04: for urolithiasis
- A61P 13/12: of the kidneys
- A61P 17/06: Antipsoriatics
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/06: Antigout agents, e.g. antihyperuricemic or uricosuric agents
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 39/02: Antidotes
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 249/12: Oxygen or sulfur atoms
- C07D 249/14: Nitrogen atoms
- C07H 7/02: Acyclic radicals
- C07H 19/06: Pyrimidine radicals
- C07H 19/16: Purine radicals
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- C07H: SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS (derivatives of aldonic or saccharic acids C07C, C07D; aldonic acids, saccharic acids C07C59/105, C07C59/285; cyanohydrins C07C255/16; glycals C07D; compounds of unknown constitution C07G; polysaccharides, derivatives thereof C08B; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification C12N15/00; sugar industry C13)

## Abstract

Described herein are compounds useful in the modulation of blood uric acid levels, formulations containing them and methods of using them. In some embodiments, the compounds described herein are used in the treatment or prevention of disorders related to aberrant levels of uric acid.

## Claims

### Claim at position 1

1-72. (canceled)

### Claim 73

A method of treating hyperuricemia associated with gout in a human, the method comprising administering to the human a compound of formula (IV):
or a pharmaceutically acceptable salt, ester, or tautomer thereof.

### Claim 74 (depends on 73)

The method of claim 73, wherein the pharmaceutically acceptable salt is administered to the human, and wherein the pharmaceutically acceptable salt is an ammonium, a primary amine, a secondary amine, a tertiary amine, a lithium, a sodium, a potassium, a calcium, a magnesium, or an aluminum salt.

### Claim 75 (depends on 74)

The method of claim 74, wherein the pharmaceutically acceptable salt is a sodium salt.

### Claim 76 (depends on 73)

The method of claim 73, wherein said administering is orally.

### Claim 77 (depends on 73)

The method of claim 73, wherein said compound is administered in combination with a pharmaceutically acceptable carrier, excipient, or diluent, in a pharmaceutical composition.

### Claim 78 (depends on 77)

The method of claim 77, wherein the pharmaceutical composition is a tablet or capsule.

### Claim 79 (depends on 77)

The method of claim 77, wherein the pharmaceutical composition is a tablet.

### Claim 80 (depends on 79)

The method of claim 79, wherein the pharmaceutical composition is a coated tablet.

### Claim 81 (depends on 79)

The method of claim 79, wherein the tablet comprises lactose.

### Claim 82 (depends on 79)

The method of claim 79, wherein the tablet comprises microcrystalline cellulose.

### Claim 83 (depends on 79)

The method of claim 79, wherein the tablet comprises sodium croscarmellose.

### Claim 84 (depends on 79)

The method of claim 79, wherein the tablet comprises gelatin.

### Claim 85 (depends on 79)

The method of claim 79, wherein the tablet comprises magnesium stearate.

### Claim 86 (depends on 79)

The method of claim 79, wherein the tablet comprises hydroxypropylcellulose or hydroxypropylmethyl-cellulose.

### Claim 87 (depends on 79)

The method of claim 79, wherein the tablet comprises polyvinyl polypyrrolidone.

### Claim 88 (depends on 73)

The method of claim 73, further comprising administering to the human a second agent effective for the treatment of hyperuricemia associated with gout.

### Claim 89 (depends on 88)

The method of claim 88, wherein the second agent is a URAT 1 inhibitor, a xanthine oxidase inhibitor, a xanthine dehydrogenase, a xanthine oxidoreductase inhibitor, or a combination thereof.

### Claim 90 (depends on 88)

The method of claim 88, wherein the second agent is allopurinol, febuxostat, FYX-051, or a combination thereof.

### Claim 91 (depends on 88)

The method of claim 88, wherein the second agent is allopurinol.

### Claim 92 (depends on 88)

The method of claim 88, wherein the second agent is febuxostat.

### Claim 93

A method of treating hyperuricemia associated with gout in a human, the method comprising administering to the human a compound of formula (IV):
